Christos N. Papandreou
Papageorgiou General Hospital(GR)
Publications by Year
Research Areas
Prostate Cancer Treatment and Research, Ubiquitin and proteasome pathways, Peptidase Inhibition and Analysis, Cancer-related Molecular Pathways, Cancer Treatment and Pharmacology
Most-Cited Works
- → The Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective(2010)972 cited
- → Phase I Trial of the Proteasome Inhibitor Bortezomib in Patients With Advanced Solid Tumors With Observations in Androgen-Independent Prostate Cancer(2004)437 cited
- → Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial(2001)395 cited
- → Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study(2016)380 cited
- → Results of a Phase II Study With Doxorubicin, Etoposide, and Cisplatin in Patients With Fully Characterized Small-Cell Carcinoma of the Prostate(2002)292 cited
- → Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression(1998)280 cited
- → Magnetic Nanoparticles in Medical Diagnostic Applications: Synthesis, Characterization and Proteins Conjugation(2015)222 cited
- → GIDEON (Global Investigation of therapeutic DE cisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis(2013)222 cited
- → Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial(2017)177 cited
- Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts.(2003)